Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, IndolentNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD30+HIV-associatedICD10C83.3C83.5C84.4C84.5C84.6C84.7C86.1C86.2C86.5C91.5-MeSHLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineNo. Substances1345 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideNo. Substances246810Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDiarrheaDyspneaEdemaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheInfectionsMucositisNeuropathyNeutropeniaOral MucositisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorCrump MHorwitz SLevine APfreundschuh MPro BVan de Wyngaert ZVelasquez WSDiseaseaggressives B-/T-NHL, Erstlinie, ECOG 0-3anaplastisches großzelliges T-Zell Lymphom, rezidiviert oder therapierefraktär, ECOG 0-1fortgeschrittenes wiederkehrendes NHLneudiagnostiziertes, HIV assoziiertes T-Zell Lymphom, Erstlinie, Karnofsky >50%peripheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3OriginDepartment of Hematology, Section of Lymphoma , M.D. Anderson Hospital, Houston, TexasDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CAFox Chase Cancer Center, Philadelphia, SGN-35 trialGerman High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)Hématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupNHL-B1 trial, DSHNHLPrincess Margaret Cancer Centre, Ontario, CanadaProtocols in Revision 8 protocols foundProtocols under revision.Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1925 V1.0)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)CHOEP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID719 V1.0)CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID821 V1.0)COMP - Cyclophosphamide 750 / Doxorubicin Liposomal 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID469 V1.0)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, T-cell lymphoma, under 70 years of age (PID71 V1.1)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)
